UCLA signed a license agreement with Theseus AI for technology developed at UCLA that uses artificial intelligence to interpret MRI scans of patients’ spines.
In this this issue we are happy to feature our spinout companies and recent initiatives like Faculty Innovation Fellow program and Bioscience Innovation Day 2019. Plus, you can read about our recent successes in outreach and licensing.
Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?
In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.
Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia
UCLA Technology Development Group is pleased to present the December 2018 issue of Innovation Magazine.
Welcome to the second Innovation Magazine from the UCLA Technology Development Group. In this issue we highlight UCLA TDG accomplishments in recent months! Our many projects are fully under way and we have established partnerships at multiple levels within the UC ecosystem, investors and with industry professionals. Featured in this issue of the magazine is storytelling and background on the TDG team, our recent deal making, what we do and how we’ve arrived at our success and growth.
In this episode, Kirsten Leute speaks with Amir Naiberg, Associate Vice Chancellor and CEO & President, UCLA Technology Development Corporation, about his experiences in technology transfer in Israel and the US.
Eighteen professors, researchers and clinicians at UCLA have been named recipients of awards from the 2017 UCLA Innovation Fund Biomedical Competition, which was established to quickly move technologies from idea to the marketplace and bridge the gap between academia and industry-investor interest to provide benefit to patients and the public.